XLON
VLG
Market cap108mUSD
Jul 10, Last price
66.50GBP
1D
0.00%
1Q
1.53%
IPO
-35.03%
Name
Venture Life Group PLC
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Bracknell, UK, in 2005, Venture Life Group plc is an international developer and marketer of diverse health and personal care items. The company's portfolio spans oral care products, dietary supplements, medical devices, dermo-cosmetics, and topical applications, serving a global market across the United Kingdom, various European countries (including the Netherlands, Germany, Italy, and Switzerland), and China. Operating through its distinct Venture Life Brands and Customer Brands divisions, the company offers a comprehensive array of solutions. These include advanced neurology-focused nutritional supplements such as NeuroAge, NeuroAge Sleep, and NeuroAge NRG, designed to enhance alertness, cognitive abilities, and mental acuity. For hair health, Original Bioscalin addresses hair loss, thinning, and baldness. The Myco Clear range provides antifungal nail solutions, comprising a Fungal Nail Solution for treatment and prevention, and a Fungal Nail Cleanser for foot and hand hygiene. In the realm of oral care, UltraDEX is formulated to combat bad breath, while Dently Dual Action is a mouthwash engineered to effectively remove plaque and bacteria. For anal discomfort, Procto-eze plus offers relief for conditions like haemorrhoids and general irritation. Venture Life also features a dedicated women's healthcare line under the vonalei brand, which includes a refreshing gel for bacterial vaginosis, a vaginal cream for atrophy, a soothing cream-gel for candidiasis (thrush), and an intimate cleansing foam. Its dermo-cosmetic selections encompass the Rosa calma brand's Cleansing Foam, Cleansing Cream, and Serum, alongside the Lubatti Classic and Lubatti Anti-age skincare collections. These skincare lines are meticulously crafted to hydrate, nourish, and recondition the skin, helping to minimize the appearance of lines and wrinkles. The company distributes its extensive product offerings through a broad network that includes international partners, pharmacies, and major grocery retailers.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||